Bradley A Fremming,Steven T Boyd
Bradley A Fremming
Merck & Co Inc is developing the cannabinoid receptor type 1 inverse agonist taranabant for the potential treatment of obesity and nicotine dependence. By October 2006, the drug had entered phase III trials for obesity, and by May 2008, a p...
Dexlansoprazole, a modified release formulation of an enantiomer of lansoprazole, for the treatment of reflux esophagitis [0.03%]
拉索唑左旋体缓释制剂治疗反流性食管炎的疗效与安全性：多中心、随机、双盲、安慰剂平行对照临床试验研究
Kwong Ming Fock,Tiing Leong Ang
Kwong Ming Fock
Takeda Pharmaceutical Co Ltd is developing dexlansoprazole, an oral controlled-release formulation of an enantiomer of lansoprazole, for the treatment of reflux esophagitis. By January 2008, an NDA for gastric acid-related diseases had been...
Kalina Venkova,Beverley Greenwood-Van Meerveld
Kalina Venkova
This review outlines recent findings related to the therapeutic potential of ghrelin agonists or antagonists for the treatment of gastrointestinal (GI) motility disorders and the regulation of the hypothalamic control of feeding. The abilit...
Hiyaa Singhee Ghosh
Hiyaa Singhee Ghosh
SIRT1 (sirtuin 1) is the human ortholog of the yeast Sir2 (silent information regulator 2) protein, which is implicated in lifespan extension in model organisms, such as yeast, worms and flies. It is an NAD+-dependent protein deacetylase wi...
Advances in immunotherapy of castration-resistant prostate cancer: bisphosphonates, phosphoantigens and more [0.03%]
新型免疫治疗在去势抵抗性前列腺癌中的应用进展：双膦酸盐、磷抗原及其他疗法
Francesco Dieli,Nadia Caccamo,Serena Meraviglia
Francesco Dieli
Medical progress has prolonged life expectancy in patients with castration-resistant prostate cancer; however, the lack of effective therapies has fuelled an intensive search for novel modalities, including immunotherapy. Human gammadelta T...
The endoplasmic reticulum as a potential therapeutic target in nonalcoholic fatty liver disease [0.03%]
内质网有望成为非酒精性脂肪肝病的治疗靶点
Christopher L Gentile,Michael J Pagliassotti
Christopher L Gentile
The endoplasmic reticulum (ER) has emerged as a key to understanding the development and consequences of hepatic fat accumulation in nonalcoholic fatty liver disease (NAFLD). An essential function of this organelle is the proper assembly of...
Free fatty acid receptor family: novel targets for the treatment of diabetes and dyslipidemia [0.03%]
游离脂肪酸受体家族：治疗糖尿病和脂质异常的新靶点
Jerome Bernard
Jerome Bernard
Free fatty acids (FFAs) fuel physiological processes in various tissues, such as skeletal muscle, the heart, liver and pancreas. Malfunction of FFA-mediated signaling pathways, as well as FFA metabolism, has been correlated to pathologies s...
Novel therapeutic agents targeting the glucocorticoid receptor for inflammation and cancer [0.03%]
针对炎症和癌症的靶向糖皮质激素受体的新疗法
Paula Sommer,David W Ray
Paula Sommer
Glucocorticoids, through their interaction with the ubiquitous glucocorticoid receptor (GR), have extensive and disparate effects on different cells and tissues. They have long been used in the treatment of asthma, arthritis and autoimmune ...
Franklyn F Bolander Jr
Franklyn F Bolander Jr
Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia [0.03%]
一种新型肽基促红细胞生成素用于治疗贫血病症
Iain C Macdougall
Iain C Macdougall
Hematide is a synthetic peptide-based erythropoiesis-stimulating agent that is being developed by Affymax Inc and Takeda Pharmaceutical Co Ltd. Hematide is undergoing phase III clinical trials for anemia.